Responses
Clinical/translational cancer immunotherapy
Original research
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.